Theravance Bioph Stock Price, News & Analysis

Theravance Biopharma (NASDAQ: TBPH) has announced it will release its fourth quarter and full year 2024 financial results and business update after market close on February 26, 2025. The company will host a conference call and simultaneous webcast at 5:00 pm EST (2:00 pm PST/10:00 pm GMT) on the same day.

Interested participants can pre-register for the telephone conference call through the provided link. The webcast will be accessible through Theravance Biopharma's website under the Investors section, Events and Presentations. A replay of the webcast will remain available on the company's website for 30 days until March 28, 2025.

Theravance Biopharma (NASDAQ: TBPH) has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference. The presentation is scheduled for Wednesday, February 12 at 12:00 pm EST (9:00 am PST/5:00 pm GMT).

Investors and interested parties can access the webcast through the Investors section under Events and Presentations on Theravance.com. The webcast recording will remain available on the company's website for 30 days following the presentation.

Theravance Biopharma (NASDAQ: TBPH) has announced that its management team will be conducting investor meetings during the 43rd Annual J.P. Morgan Healthcare Conference. The conference is scheduled to take place from January 13-16, 2025, in San Francisco, CA. Interested investors can request one-on-one meetings with the management team by contacting the company's investor relations department.

Theravance Biopharma (NASDAQ: TBPH) has announced its participation in the 7th Annual Evercore HealthCONx Conference. The company will engage in a Fireside Chat on Tuesday, December 3 at 11:15 am EST, alongside hosting in-person meetings with the investment community. The event will be accessible via webcast on Theravance.com under the Investors section, with a replay available for 30 days following the presentation.

Theravance Biopharma (NASDAQ: TBPH) reported Q3 2024 results, highlighting strong performance in key areas. YUPELRI net sales reached $62.2M, a 7% YoY increase and 14% QoQ growth. TRELEGY sales hit $789M, up 17% YoY. The company formed a Strategic Review Committee to explore alternatives for unlocking shareholder value. R&D expenses were $9.3M, while SG&A expenses stood at $16.9M. A non-cash impairment charge of $1.6M was recorded. Net loss was $12.7M, impacted by the impairment. Cash reserves totaled $91.4M. The company expects R&D expenses of $30-36M and SG&A expenses of $45-55M for full-year 2024. A settlement agreement with Qilu resolved ongoing patent litigation over YUPELRI.

Theravance Biopharma (NASDAQ: TBPH) has scheduled its third quarter 2024 financial results announcement and business update for November 12, 2024, after market close. The company will host a conference call and simultaneous webcast at 5:00 pm EST on the same day. Interested participants can pre-register for the telephone conference, while those preferring to listen via the internet can access the webcast through Theravance's website. A replay will be available online for 30 days until December 12, 2024.

Theravance Biopharma announced the publication of a sub-study of pivotal Phase 3 trials for YUPELRI (revefenacin), the first FDA-approved once-daily nebulized long-acting muscarinic antagonist (LAMA) for COPD. The study, published in the International Journal of Chronic Obstructive Pulmonary Disease, evaluated the area under the curve (AUC) lung function effects in moderate-to-very-severe COPD patients.

Key findings include:

• Revefenacin improved bronchodilation versus placebo in COPD patients
• Rapid onset of bronchodilation was observed, with a mean FEV1 difference of 145 mL at 15 minutes
• Day 84 bronchodilation improvements were sustained over 24 hours vs. placebo
• FEV1 AUC measurements provide additional information on the magnitude and consistency of bronchodilation throughout the dosing interval

The study reinforces that YUPELRI provides consistent and durable improvements in lung function over a full 24-hour period.

Theravance Biopharma (NASDAQ: TBPH) has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference in New York City. The company will engage in a Fireside Chat on Tuesday, September 10 at 10:00 am ET (7:00 am PT/3:00 pm IST). Additionally, Theravance Biopharma will host in-person meetings with the investment community during the conference.

Investors and interested parties can access a webcast of the event through the company's website, Theravance.com, under the Investors section, Events and Presentations. The webcast replay will be available on the company's website for 30 days following the event, providing an opportunity for those unable to attend live to catch up on the discussion.

Theravance Biopharma reported Q2 2024 financial results and provided a business update. YUPELRI net sales decreased 1% to $54.5 million, while Viatris collaboration revenue increased 4% to $14.3 million. The company updated its timeline for the CYPRESS study, now expecting the last patient enrollment in mid-2025. TRELEGY net sales reached $1.065 billion, increasing the likelihood of achieving up to $50 million in milestones in 2024. Theravance ended Q2 with a cash balance of $96.1 million. The company is exploring opportunities to unlock value from its Irish tax assets and has updated its 2024 financial guidance.